Prelude Capital Management, LLC Replimune Group, Inc. Transaction History

Prelude Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$23.5 - $52.65 $103,400 - $231,660	-4,400 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$18.85 - $27.0 $82,940 - $118,800	4,400 New	4,400 $101,000
Q3 2019 Nov 14, 2019	SELL	$10.01 - $16.87 $5,055 - $8,519	-505 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$12.51 - $17.28 $6,317 - $8,726	505 New	505 $7,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $693M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.